Trials / Terminated
TerminatedNCT02327182
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with mild to moderate Alzheimer's Disease (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-4666 |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-09-01
- Completion
- 2015-10-01
- First posted
- 2014-12-30
- Last updated
- 2015-11-13
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02327182. Inclusion in this directory is not an endorsement.